Cargando…

Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps

Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS definitions and yielded conflicting results. This is main...

Descripción completa

Detalles Bibliográficos
Autores principales: De Luca, Daniele, Cogo, Paola, Kneyber, Martin C., Biban, Paolo, Semple, Malcolm Grace, Perez-Gil, Jesus, Conti, Giorgio, Tissieres, Pierre, Rimensberger, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898495/
https://www.ncbi.nlm.nih.gov/pubmed/33618742
http://dx.doi.org/10.1186/s13054-021-03489-6
_version_ 1783653871585853440
author De Luca, Daniele
Cogo, Paola
Kneyber, Martin C.
Biban, Paolo
Semple, Malcolm Grace
Perez-Gil, Jesus
Conti, Giorgio
Tissieres, Pierre
Rimensberger, Peter C.
author_facet De Luca, Daniele
Cogo, Paola
Kneyber, Martin C.
Biban, Paolo
Semple, Malcolm Grace
Perez-Gil, Jesus
Conti, Giorgio
Tissieres, Pierre
Rimensberger, Peter C.
author_sort De Luca, Daniele
collection PubMed
description Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS definitions and yielded conflicting results. This is mainly due to heterogeneity in study design reflecting historic lack of pathobiology knowledge. We reviewed the available clinical and preclinical data to create an expert consensus aiming to inform future research steps and advance the knowledge in this area. Eight trials investigated the use of surfactant for ARDS in children and ten in neonates, respectively. There were improvements in oxygenation (7/8 trials in children, 7/10 in neonates) and mortality (3/8 trials in children, 1/10 in neonates) improved. Trials were heterogeneous for patients’ characteristics, surfactant type and administration strategy. Key pathobiological concepts were missed in study design. Consensus with strong agreement was reached on four statements: 1. There are sufficient preclinical and clinical data to support targeted research on surfactant therapies for PARDS and NARDS. Studies should be performed according to the currently available definitions and considering recent pathobiology knowledge. 2. PARDS and NARDS should be considered as syndromes and should be pre-clinically studied according to key characteristics, such as direct or indirect (primary or secondary) nature, clinical severity, infectious or non-infectious origin or patients’ age. 3. Explanatory should be preferred over pragmatic design for future trials on PARDS and NARDS. 4. Different clinical outcomes need to be chosen for PARDS and NARDS, according to the trial phase and design, trigger type, severity class and/or surfactant treatment policy. We advocate for further well-designed preclinical and clinical studies to investigate the use of surfactant for PARDS and NARDS following these principles. [Image: see text]
format Online
Article
Text
id pubmed-7898495
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78984952021-02-23 Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps De Luca, Daniele Cogo, Paola Kneyber, Martin C. Biban, Paolo Semple, Malcolm Grace Perez-Gil, Jesus Conti, Giorgio Tissieres, Pierre Rimensberger, Peter C. Crit Care Review Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS definitions and yielded conflicting results. This is mainly due to heterogeneity in study design reflecting historic lack of pathobiology knowledge. We reviewed the available clinical and preclinical data to create an expert consensus aiming to inform future research steps and advance the knowledge in this area. Eight trials investigated the use of surfactant for ARDS in children and ten in neonates, respectively. There were improvements in oxygenation (7/8 trials in children, 7/10 in neonates) and mortality (3/8 trials in children, 1/10 in neonates) improved. Trials were heterogeneous for patients’ characteristics, surfactant type and administration strategy. Key pathobiological concepts were missed in study design. Consensus with strong agreement was reached on four statements: 1. There are sufficient preclinical and clinical data to support targeted research on surfactant therapies for PARDS and NARDS. Studies should be performed according to the currently available definitions and considering recent pathobiology knowledge. 2. PARDS and NARDS should be considered as syndromes and should be pre-clinically studied according to key characteristics, such as direct or indirect (primary or secondary) nature, clinical severity, infectious or non-infectious origin or patients’ age. 3. Explanatory should be preferred over pragmatic design for future trials on PARDS and NARDS. 4. Different clinical outcomes need to be chosen for PARDS and NARDS, according to the trial phase and design, trigger type, severity class and/or surfactant treatment policy. We advocate for further well-designed preclinical and clinical studies to investigate the use of surfactant for PARDS and NARDS following these principles. [Image: see text] BioMed Central 2021-02-22 /pmc/articles/PMC7898495/ /pubmed/33618742 http://dx.doi.org/10.1186/s13054-021-03489-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
De Luca, Daniele
Cogo, Paola
Kneyber, Martin C.
Biban, Paolo
Semple, Malcolm Grace
Perez-Gil, Jesus
Conti, Giorgio
Tissieres, Pierre
Rimensberger, Peter C.
Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps
title Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps
title_full Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps
title_fullStr Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps
title_full_unstemmed Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps
title_short Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps
title_sort surfactant therapies for pediatric and neonatal ards: espnic expert consensus opinion for future research steps
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898495/
https://www.ncbi.nlm.nih.gov/pubmed/33618742
http://dx.doi.org/10.1186/s13054-021-03489-6
work_keys_str_mv AT delucadaniele surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps
AT cogopaola surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps
AT kneybermartinc surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps
AT bibanpaolo surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps
AT semplemalcolmgrace surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps
AT perezgiljesus surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps
AT contigiorgio surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps
AT tissierespierre surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps
AT rimensbergerpeterc surfactanttherapiesforpediatricandneonatalardsespnicexpertconsensusopinionforfutureresearchsteps